All Insights
Showing 277 - 288 of 541
Regulatory Outlook
Health and safety | UK Regulatory Outlook January 2023
Building safety | The Building Safety Act | Fire safety
Regulatory Outlook
Fintech, digital assets, payments and consumer credit | UK Regulatory Outlook January 2023
Edinburgh reforms | Extending confirmation of payee service to additional payment service providers | Measures to combat authorised push payment
Regulatory Outlook
Competition | UK Regulatory Outlook January 2023
Horizontal regulations | Subsidy control | EU market definition notice
Online Safety
UK Online Safety Bill to have more teeth
New criminal sanctions for senior managers to be introduced by government
Digital Transformation Projects
Digital Transformation Projects | The Legal Angles
Digital transformation is at the heart of future-focused business strategy. But just what do we mean by “digital transformation”? Our
Knowledge Notes
UK business law predictions for 2023
As the new year unfolds, we look ahead at what legal developments businesses can expect
Tech, Media and Comms
A new reality dawns for Polish e-commerce in 2023
Businesses and consumers in Poland will need to adjust to the implementation of three new European regulations
Future-proofing supply chains
How to protect against counterfeit goods in distressed supply chains
A clear and robust IP strategy can help to fight the recent proliferation of infringements across international trade
The Built Environment
A look ahead for UK real estate in 2023
The new year will be a busy one – including the implementation of new regimes for overseas ownership of UK
Financial Services
EU financial services firms face tougher cybersecurity rules in two years
The European authorities have adopted rules on digital operational resilience to tackle risks and harmonise requirements
Financial Services
FTX – another warning shot for crypto audits?
The recent collapse of crypto-exchange FTX highlights the risks associated with auditing crypto-currency businesses
Life Sciences and Healthcare
Products without an intended medical purpose: EU clarifies conditions
Non-medical product manufacturers have limited time to prepare for new risk management and clinical data obligations
